Bowel Cancer Screening Programme announces first results

December 8, 2011 in Cancer

The Bowel Cancer Screening Programme in England is on track to cut bowel cancer deaths by its target of 16%, reveals an analysis of the first one million test results, published in Gut.

But the results also show a much higher proportion of cancers detected were left sided, suggesting that different strategies may need to be deployed to pick up disease on both sides of the body, as right sided cancers are thought to be more aggressive, say the authors.

kills 16,000 people every year in the UK and is second only to as the leading cause of in both the UK and Europe.

Survival from bowel cancer is still only around 50% in the UK, and significantly lower than in other comparable countries.

The authors base their findings on an analysis of the first 1.08 million faecal occult blood tests, returned by patients invited for the first round of bowel in England.

The programme started in 2006 and was rolled out nationwide by the end of 2009 for those between the ages of 60 and 69. It involves three tests every two years, and has since been extended to those over 70.

Up to October 2008, over two million people had been invited to participate, with around half of those invitations accepted - just under 50% for men and almost 55% for women.

Returns were higher in the four provincial hubs, averaging 55-60%, but were lower in London, where they averaged 40%.

In all, 2.5% of men and 1.5% of women (21,106 people in all) had an abnormal test result out of the 1.08 million returns, and 17,518 people were investigated further.

Most underwent - a procedure involving a long tube with a camera on the end that is inserted into the back passage.

Men were more likely to have cancer and its immediate ("higher risk ") than women.

These were found in around one in eight (11.6%) and around four out of 10 (43%) men, respectively, compared with just under 8% and 29%, respectively, of the women.

Seven out of 10 cancers (71%) picked up by the screen were early stage disease, and as expected, right sided cancer was more common in women than in men.

But left sided cancers were considerably more common than expected, based on figures drawn from cancer registries.

These figures indicated that around two thirds of bowel cancers (67%) picked up by the screening programme would be left sided and around one in four (24%) would be right sided.

Instead, more than three out of four (77%) cancers detected by screening were left sided, compared with 14% that were right sided.

The authors point to research suggesting that right sided cancers are more aggressive and less likely to be picked up by screening. "Different screening strategies may be required to effectively screen for right-sided bowel cancer," they conclude.

Provided by British Medical Journal search and more info website

not rated yet  

Rank not rated yet
Related Stories
Relevant PhysicsForums posts

More news stories

New smartphone application improves colonoscopy preparation

The use of a smartphone application significantly improves patients' preparation for a colonoscopy, according to new research presented today at Digestive Disease Week (DDW). The preparation process, which begins days in ...

Cancer created 12 hours ago | popularity not rated yet | comments 0

Research examines new methods for managing digestive health

Research presented at Digestive Disease Week (DDW) explores new methods for managing digestive health through diet and lifestyle.

Cancer created 12 hours ago | popularity not rated yet | comments 1

New colonoscope provides ground-breaking view of colon

A ground-breaking advance in colonoscopy technology signals the future of colorectal care, according to research presented today at Digestive Disease Week(DDW). Additional research focuses on optimizing the minimal withdrawal ...

Cancer created May 18, 2013 | popularity 5 / 5 (2) | comments 0

ASCO: combo antibody therapy effective for melanoma

(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in ...

Cancer created May 17, 2013 | popularity not rated yet | comments 0

Risk factors ID'd for poor cutaneous cell CA outcomes

(HealthDay)—The risks of metastasis and death associated with cutaneous squamous cell carcinoma (CSCC) are low, but significant, and risk factors for poor outcome include tumor diameter, invasion beyond ...

Cancer created May 17, 2013 | popularity not rated yet | comments 0 | with audio podcast


Computational tool translates complex data into simplified 2-dimensional images

In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual ...

New theory on genesis of osteoarthritis comes with successful therapy in mice

Scientists at Johns Hopkins have turned their view of osteoarthritis (OA) inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, ...

Researchers identify a potential new risk for sleep apnea: Asthma

Researchers at the University of Wisconsin have identified a potential new risk factor for obstructive sleep apnea: asthma. Using data from the National Institutes of Health (Heart, Lung, and Blood Institute)-funded Wisconsin ...

Study finds that sleep apnea and Alzheimer's are linked

A new study looking at sleep-disordered breathing (SDB) and markers for Alzheimer's disease (AD) risk in cerebrospinal fluid (CSF) and neuroimaging adds to the growing body of research linking the two.

Ginger compounds may be effective in treating asthma symptoms

Gourmands and foodies everywhere have long recognized ginger as a great way to add a little peppery zing to both sweet and savory dishes; now, a study from researchers at Columbia University shows purified components of the ...

'Gap' for HIV vaccine efforts after latest setback

The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.